AHA: American Heart Association
Conference Coverage
Why STEMI patients benefit from PCI of nonculprit lesions
“This immediately explains the clinical benefit observed with preventive PCI in STEMI patients with multivessel disease.” – Dr. Frans Van de Werf...
Conference Coverage
Cardiac biomarkers refine antihypertensive drug initiation decisions
PHILADELPHIA – Analysis showcases a better way to select patients for intensive BP lowering.
Conference Coverage
Framingham: Exercise lessens cardiometabolic risk of poor diet
PHILADELPHIA –
Conference Coverage
Testosterone gel increases LV mass in older men
PHILADELPHIA – The clinical implications of this hormonal therapy–induced jump in left ventricular mass remain unclear.
Conference Coverage
SPRINT-type BP control provides up to 3 years of additional life
PHILADELPHIA – Survival advantage of intensive over standard blood pressure lowering is age dependent.
Conference Coverage
Pharmacist BP telemonitoring cut cardiovascular events, turned profit
PHILADELPHIA – Was the 51% reduction in major cardiovascular events a fluke?
Conference Coverage
PACT-HF: Transitional care derives no overall benefit
PHILADELPHIA –
Conference Coverage
Analyses clarify who benefits from ARNI-ARB combination
PHILADELPHIA –
Conference Coverage
ODYSSEY Outcomes: Alirocumab cut stroke, PAD, VTE
PHILADELPHIA – Prespecified outcomes from the alirocumab outcomes trial showed the drug significantly cut PAD and VTE events, as well as ischemic...
Conference Coverage
New hypertension performance measures boost 130/80 mm Hg target
PHILADELPHIA – Hypertension performance and quality measures from the AHA and ACC provide a guide for implementing the 2017 hypertension guideline...
Conference Coverage
Navigators improve medication adherence in HFrEF
PHILADELPHIA –
Conference Coverage
Bariatric surgery tied to fewer cerebrovascular events
PHILADELPHIA –
Conference Coverage
New heart failure trial data presage guideline revisions
PHILADELPHIA –
Conference Coverage
Cardiac arrests peak with pollution in Japan
PHILADELPHIA –
Conference Coverage
Icosapent ethyl cost effective in REDUCE-IT analysis
PHILADELPHIA – Treatment with the fish-derived drug for CV event reduction is more effective and less costly than placebo.